Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:2307-2315
Published online before print April 16, 2007, doi: 10.1161/CIRCULATIONAHA.107.694596
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
115/17/2307    most recent
CIRCULATIONAHA.107.694596v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Funakoshi, H.
Right arrow Articles by Feldman, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Funakoshi, H.
Right arrow Articles by Feldman, A. M.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ADENOSINE 5'-PHOSPHATE
Related Collections
Right arrow Biochemistry and metabolism
Right arrow Congestive

(Circulation. 2007;115:2307-2315.)
© 2007 American Heart Association, Inc.


Molecular Cardiology

A1 Adenosine Receptor Upregulation Accompanies Decreasing Myocardial Adenosine Levels in Mice With Left Ventricular Dysfunction

Hajime Funakoshi, MD, PhD; Lefteris C. Zacharia, PhD; Zhonghua Tang, MD, PhD; Jin Zhang, PhD; Ling L. Lee, MS; Julie C. Good, MS; David E. Herrmann, MS; Yoshihiro Higuchi, MD, PhD; Walter J. Koch, PhD; Edwin K. Jackson, PhD; Tung O. Chan, PhD; Arthur M. Feldman, MD, PhD

From the Center for Translational Medicine, Department of Medicine, Jefferson Medical College, Philadelphia, Pa (H.F., Z.T., J.Z., L.L.L., J.C.G., D.E.H., W.J.K., T.O.C., A.M.F.); Medical Institute of Bioregulation, Kyushu University, Kyushu, Japan (Y.H.); and Center for Clinical Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, Pa (L.C.Z., E.K.J.).

Correspondence to Arthur M. Feldman, MD, PhD, or Tung O. Chan, PhD, Department of Medicine, Jefferson Medical College, 1025 Walnut St, Ste 822 College, Philadelphia, PA 19107. E-mail Arthur.Feldman{at}Jefferson.edu or Tung.Chan@Jefferson.edu

Received February 9, 2007; accepted February 23, 2007.

Background— It is well known that adenosine levels are increased during ischemia and protect the heart during ischemia/reperfusion. However, less is known about the role of adenosine–adenosine receptor (AR) pathways in hearts with left ventricular dilation and dysfunction. Therefore, we assessed adenosine levels and selective AR expression in transgenic mice with left ventricular systolic dysfunction secondary to overexpression of tumor necrosis factor-{alpha} (TNF 1.6).

Methods and Results— Cardiac adenosine levels were reduced by 70% at 3 and 6 weeks of age in TNF 1.6 mice. This change was accompanied by a 4-fold increase in the levels of A1-AR and a 50% reduction in the levels of A2A-AR. That the increase in A1-AR density was of physiological significance was shown by the fact that chronotropic responsiveness to the A1-AR selective agonist 2-chloro-N6-cyclopentanyladenosine was enhanced in the TNF 1.6 mice. Similar changes in adenosine levels were found in 2 other models of heart failure, mice overexpressing calsequestrin and mice after chronic pressure overload, suggesting that the changes in adenosine-AR signaling were secondary to myocardial dysfunction rather than to TNF overexpression.

Conclusions— Cardiac dysfunction secondary to the overexpression of TNF is associated with marked alterations in myocardial levels of adenosine and ARs. Modulation of the myocardial adenosine system and its signaling pathways may be a novel therapeutic target in patients with heart failure.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. T. Fassett, X. Xu, X. Hu, G. Zhu, J. French, Y. Chen, and R. J. Bache
Adenosine regulation of microtubule dynamics in cardiac hypertrophy
Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H523 - H532.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
F Franceschi, J-C Deharo, R Giorgi, Y By, C Monserrat, J Condo, Z Ibrahim, A Saadjian, and R Guieu
Peripheral plasma adenosine release in patients with chronic heart failure
Heart, April 1, 2009; 95(8): 651 - 655.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
X. Xu, J. Fassett, X. Hu, G. Zhu, Z. Lu, Y. Li, J. Schnermann, R. J. Bache, and Y. Chen
Ecto-5'-Nucleotidase Deficiency Exacerbates Pressure-Overload-Induced Left Ventricular Hypertrophy and Dysfunction
Hypertension, June 1, 2008; 51(6): 1557 - 1564.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. R. DeGeorge Jr, E. Gao, M. Boucher, L. E. Vinge, J. S. Martini, P. W. Raake, J. K. Chuprun, D. M. Harris, G. W. Kim, S. Soltys, et al.
Targeted Inhibition of Cardiomyocyte Gi Signaling Enhances Susceptibility to Apoptotic Cell Death in Response to Ischemic Stress
Circulation, March 18, 2008; 117(11): 1378 - 1387.
[Abstract] [Full Text] [PDF]